Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
OMOmeros Corporation logo

Omeros Corporation (OMER)

NASDAQ Global Market · Currency in USD
$16.57 ▼ -0.29 (-1.72%)
At close: Oct 23, 4:00 PM ET. Market closed.
$16.77 ▲ +0.20 (+1.21%)
After hours: Oct 23, 7:36 PM ET

Summary

Previous Close
$16.86
Open
$16.59
Day's Range
$16.37 – $16.80
52 Week Range
$6.24 – $21.24
Volume
698,891
Avg. Volume
1,744,907
Market Cap
$1.20B
Beta (5Y Monthly)
2.57
PE Ratio (TTM)
8.68
EPS (TTM)
$1.73
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$27.50

Profile: Omeros Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
175
CEO
Gregory A. Demopulos
Website
omeros.com

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate $0.03 · Revenue est. $37.28M
DateEst.Actual
Aug 13, 2026-$0.27$0.15Beat
May 13, 2026-$0.40-$0.24Beat
Mar 31, 2026-$0.55$3.14Beat
Nov 13, 2025-$0.58-$0.47Beat
Aug 14, 2025-$0.55-$0.43Beat
May 15, 2025-$0.57-$0.58Miss

Analyst view

Consensus price target
$27.50 ▲ +66.0%
Range $22.00 – $33.00
Rating: Buy
Buy 63% · Hold 26% · Sell 11%

Get free alerts on OMER and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.